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Contribution of transgenic models to understanding human prion disease
Transgenic mice expressing human prion protein in the
absenceof endogenousmouseprionproteinfaithfullyrep-
licate human prions. These models reproduce all of the
key features of human disease, including long clinically
silent incubation periods prior to fatal neurodegeneration
with neuropathological phenotypes that mirror human
prion strain diversity. Critical contributions to our under-
standing of human prion disease pathogenesis and aetiol-
ogy have only been possible through the use of transgenic
mice.These models have provided the basis for the confor-
mational selection model of prion transmission barriers
and have causally linked bovine spongiform encephalopa-
thy with variant Creutzfeldt-Jakob disease. In the future
these models will be essential for evaluating newly identi-
ﬁed potentially zoonotic prion strains, for validating
effective methods of prion decontamination and for devel-
oping effective therapeutic treatments for human prion
disease.
Keywords: Creutzfeldt-Jakob disease, fatal familial insomnia, Gerstmann-Sträussler-Scheinker disease, kuru, prion,
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Introduction
Prions have attracted immense research interest for many
years because of their unique composition and properties
–beingapparentlydevoidof signiﬁcantnucleicacid[1–5].
According to the widely accepted ‘protein-only’ hypoth-
esis [6], host-encoded cellular prion protein (PrP
C) is con-
verted to an alternative form designated PrP
Sc [1–5]. It is
proposed that PrP
Sc is the infectious agent acting to repli-
cateitself withhighﬁdelitybyrecruitingendogenousPrP
C
and that the difference between these isoforms lies purely
inthemonomerconformationanditsstateof aggregation
[1–5,7–9]. Notably however, although abnormal isoforms
of PrPareundoubtedlythemajorconstituentof mamma-
lian prions, it has not yet been excluded that other mol-
ecules may contribute to infectious prion composition or
may be required to direct the assembly of PrP
Sc [10–12].
Inthisregardthepreciseidentiﬁcationof minor‘contami-
nants’ that co-purify with PrP
Sc may still be of critical
importance to understanding infectious prion composi-
tion, the determinants of prion strain or the ability of a
prion to infect a host [13].
Central to understanding prion propagation remains
the conundrum of prion strains – how a protein-only
infectious agent can encode information required to
specifydistinctdiseasephenotypes–andalsotheso-called
species barrier effect which limits cross species infection.
While originally considered different aspects of the prion
problem it is now clear that species barriers and prion
strainsareintimatelyrelatedby‘conformationalselection’
[5,14]. This hypothesis proposes that although a wide
range of mammalian PrP
Sc conformations may be pos-
sible,onlyasubsetwillbecompatiblewitheachindividual
PrP primary structure. Ease of transmission of prions
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polymorphisms), therefore relates to overlap of permis-
sible PrP
Sc conformations between the structures of PrP
from the source and recipient as well as heterogeneity in
cellular mechanisms affecting prion propagation and
clearance kinetics [5,14]. Importantly, conformational
selection has now been strongly supported by elegant
studies of prions in yeast and other fungi [15–17] and
intriguingly evidence for strains in Alzheimer’s disease is
alsonowemerging,withself-propagatingvariationsinthe
structure of amyloid-b ﬁbrils appearing to correlate with
differences in cyto-toxicity [18] and patterns of amyloid
deposition in transgenic mice [19]. Elucidation of the
composition and structure of infectious mammalian
prions will therefore not only provide a major advance to
understanding the molecular mechanism of prion repli-
cation,withdirecttranslationalbeneﬁtsforbothdiagnosis
and rational therapeutics, but will also be of great rel-
evance to a wide range of other neurodegenerative dis-
eases involving accumulation of misfolded host proteins
[5,20,21].Indeed,evidenceforcommonalityof structural
features in protein misfolding diseases is provided already
byantibodiesraisedagainstoligomericformsof PrPwhich
detect soluble oligomeric forms of a number of other
amyloid proteins [22]. More recently it has been proposed
that PrP
C may play a critical role in the pathogenesis of
Alzheimer’s disease by mediating amyloid-b oligomer
induced synaptic dysfunction [23].
Aside from the intrinsic biological interest of studying
prions, human prion disease is a strategic priority for
public health protection. The occurrence of variant
Creutzfeldt-Jakob disease (vCJD) [24] and the experimen-
tal conﬁrmation that it is caused by the same prion strain
as that causing bovine spongiform encephalopathy (BSE)
in cattle [25–28], has dramatically established the
zoonoticpotentialof animalpriondiseases.Theextremely
prolonged and variable incubation periods seen in human
prion disease and the possibility of subclinical carrier
states means that it will be some years before the full con-
sequences of human exposure to BSE prions are known
[14,29–33]. In the meantime, we are faced with the pos-
sibility that signiﬁcant numbers in the population may be
incubating this disease and that they might pass it on to
others via blood transfusion, blood products, tissue and
organ transplantation and other iatrogenic routes
[14,33–40]. Notably, while cattle BSE is now effectively
controlled, the emergence of other new or newly recog-
nized potentially zoonotic animal prion strains remains a
key issue for public health. A number of novel isolates of
bovine prion disease have now been identiﬁed which
appear to be distinct prion strains [41–44] and the host
range of atypical sheep prions [43,45,46] has not been
established. Because prion strains can adapt and mutate
on passage in new species [5,43,47], and also within
speciesasaresultof PrPpolymorphismsandothergenetic
factors [28,48–51], the evaluation of their risks to public
health is complex. The demonstration of subclinical
carrier states of prion infection in animal models is also
relevant to public health, both with respect to prion
zoonoses and iatrogenic transmission of human prions
[28,33,39,52]. Prions resist many conventional steriliza-
tion procedures and effective methods for prion decon-
tamination of surgical instruments and medical
equipment although reported have yet to be effectively
implemented [53,54].
In order to understand the molecular basis of human
prion disease, develop rational therapeutics, improved
decontamination methods and diagnostic tools, effective
and appropriate experimental models are essential.
However, very few alternative experimental approaches
are available for studying prion diseases as incubation
time, clinical phenotype, neuropathology, immune
responsesandbehaviourcanonlybestudiedinananimal.
Early studies of human prions used primates [55–57];
however, following the demonstration in 1995 that the
species barrier limiting transmission of human prions to
wild-type mice can be obviated by expression of human
PrPintheabsenceof endogenousmousePrP[58,59]such
‘humanised’transgenicmicehavebecomekeyexperimen-
tal models for studying human prion disease [43,60–65].
Two types of genetic modiﬁcation can be used to generate
human PrP-expressing mice, either transgenic expression
of humanPrPonamousePrPknockoutbackground[62]
ordirectreplacementof mousePrPwithhumanPrPusing
gene knock-in technology [61].
Determinants of phenotypic variability in
human prion disease
Human prion diseases include Creutzfeldt-Jakob disease
(CJD), Gerstmann-Sträussler-Scheinker disease (GSS),
fatal familial insomnia, kuru and vCJD in humans
[1,2,39].They are associated with a range of clinical pre-
sentations and are classiﬁed by both clinico-pathological
syndrome and aetiology with subclassiﬁcation according
to molecular criteria [39,66] (Table 1). The clinical pre-
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thereisconsiderableoverlapobservedbetweenindividuals
with different disease aetiologies [33,39,66,67] and even
infamilymemberswiththesamepathogenicPRNPmuta-
tion [67–74]. Remarkably, kuru demonstrates that incu-
bation periods of infection with human prions can exceed
50 years [32,75]. Progressive dementia, cerebellar ataxia,
pyramidal signs, chorea, myoclonus, extrapyramidal
features, pseudobulbar signs, seizures and amyotrophic
features can be seen in variable combinations. Criteria
used for diagnosis of human prion disease have been
deﬁned [39,76] and deﬁnite diagnosis of sporadic and
acquired prion disease relies upon neuropathological
examination and the demonstration of pathological PrP
deposition in the central nervous system by either immuno-
blotting or immunohistochemistry [39,76–79] (Figure 1).
Figure 1. Variant Creutzfeldt-Jakob disease (vCJD) is a distinct human prion strain. (a) Immunoblot of proteinase K digested brain
homogenates using antiPrP monoclonal antibody 3F4 showing PrPSc types 1–4 in human brain according to the London classiﬁcation [90].
Types 1–3 PrPSc are seen in the brain of classical forms of CJD (either sporadic or iatrogenic CJD) and kuru, while type 4 PrPSc is uniquely
seen in vCJD brain [25,90,122]. (b,c) Brain sections from sporadic CJD (b) and vCJD (c) showing abnormal PrP accumulation following
immunohistochemistry using antiPrP monoclonal antibody ICSM35. Abnormal PrP deposition in sporadic CJD most commonly presents as
diffuse, synaptic staining, whereas vCJD is distinguished by the presence of ﬂorid PrP plaques consisting of a round amyloid core surrounded
by a ring of spongiform vacuoles. Scale bars: 50 mm. (d) Distribution of PrP
Sc in human tissues. The schematic diagram shows tissues in
which PrP
Sc has been detected using high sensitivity immunoblotting. The vCJD has a peripheral pathogenesis distinct from classical forms of
CJD, with a prominent and uniform involvement of lymphoreticular tissues.
Table 1. Classiﬁcation of human prion disease
Aetiology Phenotype Frequency References
Sporadic
Unknown: random distribution
worldwide; incidence of 1–2 per
million per annum
Sporadic CJD: subacute myoclonic
form and range of atypical forms;
multiple distinct prion strains
associated with distinct
clinicopathological phenotypes
which include sporadic fatal
insomnia
Approximately 85% [39,66,85,217]
Inherited
Autosomal dominantly inherited
conditions with high penetrance;
all forms have germline PRNP
coding mutations
Extremely variable: readily mimics
familial Alzheimer’s disease and
other neurodegenerative
conditions; over 30 mutations
identiﬁed; includes GSS, familial
CJD and FFI
10–15% [39,66,67,72]
Acquired
Iatrogenic infection with human
prions via medical or surgical
procedures; cadaveric derived
pituitary hormones, tissue grafts,
and contaminated neurosurgical
instruments
Iatrogenic CJD: typical CJD when
direct central nervous system
human exposure; ataxic onset
when peripheral infection
<5% (most from USA, UK, France
and Japan)
[39,120,225]
Exposure to human prions via
endocannibalism
Kuru Unique to small area of Papua New
Guinea; major epidemic in 1950s
with gradual decline since
cessation of cannibalism
[32,39,75,226,227]
Exposure (presumed dietary) to
BSE prion strain; probable
secondary transmission via
blood transfusion and possibly
blood products
Variant CJD Mainly UK with patients in several
other countries
[14,24,33,39,40]
BSE,bovinespongiformencephalopathy;CJD,Creutzfeldt-Jakobdisease;FFI,fatalfamilialinsomnia;GSS,Gerstmann-Sträussler-Scheinkerdisease.
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either methionine (M) or valine (V)] powerfully affects
susceptibility to human prion diseases [80–85]. About
38% of northern Europeans are homozygous for the
more frequent methionine allele, 51% are heterozygous,
and 11% homozygous for valine. Homozygosity at PRNP
codon129predisposestothedevelopmentof sporadicand
acquired CJD [80–85] and is most strikingly observed
in vCJD where all neuropathologically conﬁrmed cases
studied so far have been homozygous for codon 129
methionine of PRNP [38,39,49,50].
Prion strains are classically distinguished by distinct incu-
bationperiodsandbypatternsof neuropathologicaltargeting
(so-called lesion proﬁles) in a panel of deﬁned inbred mouse
lines [86]. Common histopathological features involve a
classical triad of spongiform vacuolation (affecting any
partof thecerebralgreymatter),neuronalloss,andastro-
cyticandmicroglialproliferationandmaybeaccompanied
by amyloid plaques composed of insoluble aggregates of
PrP [77,87]. Amyloid plaques are a notable feature of
kuru and GSS [77,88,89] but they are less frequently
found in the brains of patients with sporadic CJD which
typically show a diffuse pattern of PrP deposition [77,90]
(Figure 1).Thehistopathologicalfeaturesof vCJDarerela-
tively consistent when compared to sporadic CJD and dis-
tinguish it from other human prion diseases. The most
distinctivefeatureisthepresenceof largenumbersof PrP-
positive amyloid plaques that differ in morphology from
the plaques seen in kuru and GSS in that the surrounding
tissue takes on a microvacuolated appearance, giving the
plaques a ﬂorid appearance [24,91] (Figures 1 and 2).
Difﬁculties in assigning human prion strains
The hypothesis that alternative conformations or assem-
bly states of PrP
Sc provide the molecular substrate for a
signiﬁcant part of the clinicopathological heterogeneity
seen in human prion diseases and that this relates to the
existence of distinct human prion strains is supported by
considerable experimental evidence [1–5,25,92–95] and
also by the demonstration of protein conformation-based
inheritance mechanisms of yeast prions [15–17]. Despite
these advances, the precise molecular basis of mamma-
lian prion strain diversity is unknown. A major confound-
ing issue in this regard has been in resolving whether
relatively subtle biochemical differences in PrP
Sc are of
biological importance and accurately reﬂect the propaga-
tion of distinct human prion strains. This is particularly
true in sporadic CJD [25,90,93,96–100] where progress
has been severely hampered by a lack of transgenic
modellingdatatoﬁrmlydistinguishtheidentityof distinct
prion strains and their deﬁning molecular and neuro-
pathological phenotypes. This fundamental problem
coupled with the difﬁculties and variability of the bio-
chemical methods used to distinguish PrP
Sc types [90,96–
98,100–102] has so far precluded an internationally
accepted classiﬁcation system for human prion strains. In
this regard, the increasingly recognized co-occurrence of
differentPrP
Sctypesinthesamebrain[74,85,90,93,102–
108] and the recognition that protease-sensitive patho-
logical isoforms of PrP (distinct from prototypical PrP
Sc)
may have a signiﬁcant role in both animal and human
prion disease [94,99,109–116] has further confounded
progress. All of these factors, together with the known
ability of genetic background to inﬂuence prion strain
selection [28,50,51,117–119] and knowledge that route
of transmission in acquired human prion disease may
dramatically inﬂuence clinical and neuropathological
presentation [120–123], has re-emphasized the require-
ment to remove host variability by identifying distinct
prion strains in appropriate transgenic models.
Transgenic modelling has made key
contributions to understanding prion biology
Considerable evidence argues that prions are composed
largely, if not entirely, of abnormal isoforms of PrP
Figure 2. Human prion protein with valine at residue 129 prevents expression of the variant Creutzfeldt-Jakob disease (vCJD) phenotype.
Primary and secondary transmission of vCJD prions to transgenic Tg(HuPrP129M+/+ Prnp°
/°)-35 mice (Tg35) results in faithful propagation
of type 4 PrP
Sc and the occurrence of abundant ﬂorid PrP plaques throughout the cortex that are the neuropathological hallmark of vCJD
[49]. In contrast, primary transmission of vCJD prions to transgenic Tg(HuPrP129V+/+ Prnp°/°)-152 mice (Tg152) produces a novel prion
strain that is maintained on secondary passage in the same mice distinguished by the propagation of type 5 PrP
Sc and a distinct pattern of
neuropathology characterized by large nonﬂorid PrP plaques restricted to the corpus callosum [26,49]. (a,b) Representative immuno-blots of
proteinase-K treated brain homogenates from variant CJD and transgenic mice analysed with antiPrP monoclonal antibody 3F4. The
identity of the brain sample is designated above each lane with the type of PrP
Sc present in the sample designated below using the London
classiﬁcation [90]. (c,d) Representative immunohistochemical analysis of transgenic mouse brain at secondary passage showing abnormal
PrP plaques stained with antiPrP monoclonal antibodies ICSM 35 (a)o r3 F 4( b). Scale bars: 100 mm.
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gation and pathogenesis is demonstrated by the fact that
knockout mice lacking the PrP gene (Prnp°
/° mice) are
entirely resistant to prion infection [124,125] and that
reintroduction of PrP transgenes restores susceptibility to
infection in a species-speciﬁc manner that allows reverse
genetics approaches to studying structure-function rela-
tionships in PrP (for reviews see [62,65,126]). PrP in its
entirety is unnecessary for prion propagation. Not only
can the unstructured N-terminal 90 amino acids be
deleted [127,128], but also the ﬁrst a-helix, the second
b-strand and part of helix 2. In transgenic animals, a
106 amino acid fragment of the protein comprising
PrPD23–88 and D141–176 conferred susceptibility to
and propagation of prions [129,130]. Notably while
expression of PrP N-terminal deletion mutants to residue
106 are tolerated and support prion propagation
[127,128], deletion beyond this leads to severe ataxia and
neuronal loss in the granular cell layer of the cerebellum
[62,131]. Intriguingly, the Doppel protein (Dpl) [132],
which has a similar structure to N-terminally truncated
PrP, causes a similar cerebellar effect when ectopically
expressedinthebrain[133].Theseverityof neurotoxicity
correlates with the level of Dpl expression [134] and can
be rescued by PrP
C expression [135], indicating that PrP
C,
Dpl and DPrP might compete for a common hypothetical
receptor or ligand LPrP that transduces neuroprotective
signals when bound to PrP
C but not when bound to Dpl or
DPrP [62,131,136,137]. This model also proposes the
existence of a PrP
C-like protein termed P that is capable
of compensating for the absence of PrP
C in Prnp°
/° mice.
Recently the protein Sho has been demonstrated to be a
glycosylphosphatidylinositol (GPI)-anchored neuronal
glycoprotein present in the central nervous system (CNS)
from early postnatal life that can counteract the neuro-
toxic effects of either Dpl or DPrP and is therefore a candi-
date for P [138].
While PrP expression is absolutely required for prion
propagation and neurotoxicity [124] knockout of PrP
C in
embryonic models [139,140] or in adult brain [141] has
no overt phenotypic effect that inﬂuences lifespan or fer-
tility.Theseﬁndingsdemonstratethatacutelossof PrP
Cin
neurones in adulthood is tolerated, and that the neuro-
pathophysiology of prion diseases is not due to loss of
PrP
C function [142,143]. Prnp°
/° mice are not normal,
however (for reviews see [2,62,144,145]). In particular,
in addition to a role for PrP
C in providing neuroprotective
signals, abnormalities in synaptic physiology, circadian
rhythms, cognition and olfactory physiology have been
reported [146–153]. Notably, a reduction of slow afterhy-
perpolarizations evoked by trains of action potentials in
hippocampalneuronesinPrnp°
/°miceduetodisruptionof
calcium-activated potassium currents is also affected by
theconditionalknockoutof PrP
Csuggestingthatthisphe-
notype is speciﬁcally due to the absence of PrP
C, reﬂecting
loss of a differentiated neuronal function, rather than a
developmental deﬁcit arising from congenital knockout of
PrP
C [141]. Important functional correlates of abnor-
malities of synaptic transmission in Prnp°
/° mice include
cognitivedeﬁcits[152]andimpairmentof olfactoryphysi-
ologyandbehaviour[153]whichcanberescuedbytrans-
genic neuronal expression of PrP
C. Very recently it has
been revealed that axonal PrP
C expression is required for
peripheral myelin maintenance [154] and this ﬁnding
correlates strongly with earlier demonstrations of exten-
sive demyelination in transgenic mice expressing PrP
with deletion mutants in the central domain [155–157].
Importantly, despite current uncertainties regarding the
conversion of PrP
C to PrP
Sc and possible mechanisms of
neurotoxicity [5], the prevention of this conversion in
neurones by conditional knock out of PrP
C has been
shown to prevent disease progression and reverse early
degenerative changes [142].These data have ﬁrmly estab-
lished PrP
C as the prime target for rational therapeutics in
prion disease [143,158,159]. Conversely, although PrP
Sc
has long been considered as a target for chemotherapy
[158], drugs interacting with PrP
Sc are likely to be prion
strain-speciﬁc and may only target a speciﬁc subset of
PrP
Sc conformers resulting in propagation of drug resis-
tant prions [143,160].
Human PrP transgenic mouse models
Sporadic CJD prions transmit disease only occasionally to
wild-type mice with long and variable incubation periods
[26,58,59,122,161]. Early attempts to transmit human
prions to transgenic mice met with varied success.Tg(Hu-
PrP)110 and Tg(HuPrP)152 transgenic lines were made
by co-expressing wild-type human PrP with valine at
codon 129 in mice also expressing endogenous mouse
PrP
C [161]. However after inoculation with brain homo-
genates from patients with GSS and sporadic and iatro-
genic CJD these transgenic recipients showed no higher
frequency of disease than inoculated nontransgenic
control mice. This lack of susceptibility of Tg(HuPrP)
mice, together with the earlier pioneering work of Scott
582 J. D. F. Wadsworth et al.
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generate mice that expressed a chimeric PrP protein in
which a segment of mouse PrP
C was replaced with the
corresponding human PrP sequence [161]. When simi-
larly inoculated with CJD prions, all the Tg(MHu2MPrP)
mice developed neurological disease around 200 days
post-inoculation [161]. Concomitant with this chimeric
transgene approach, the endogenous mouse PrP allele
was also removed by breeding Tg(HuPrP)152 mice to
PrP null mice (Prnp°
/°) to produce homozygous
Tg(HuPrP)152/Prnp°
/° [58,59]. These mice were found
to be highly susceptible to CJD prions, with all inoculated
mice succumbing to disease at short incubation periods
[58,59]. Although the chimeric transgene approach
has provided extremely important advances to our
understanding of human prion strain propagation
[59,92,161,163,164], the demonstration that the
human to mouse transmission barrier is overcome simply
by expressing human PrP
C in the absence of endogenous
mouse PrP
C [58,59] has established this as the most
straightforward approach for investigating human prion
strain diversity. Importantly, this approach enables the
effects of genotype in the inoculum and recipient trans-
genic mouse to be modelled deﬁnitively to provide key
information on the role of human PrP primary structure
in inﬂuencing prion strain propagation [2,5,33,60]. More
recently, other human PrP
C-expressing mouse models
have been generated using knock-in technology which
allows transgene integration at the normal genomic loca-
tion and endogenous levels of expression under the
control of normal gene regulatory elements [61,63,165–
167]. Both transgenic and knock-in modelling of prion
diseases provide complimentary results in most cases;
however, over-expression of human PrP transgenes may
be desirable. Over-expression results in considerable trun-
cation in incubation periods such that these models are
more convenient in practice and in some instances trans-
mission may require over-expression. For instance, trans-
mission of BSE prions to human PrP knock-in mice
resulted in no infection [63] whereas the transgenic
approach has clearly demonstrated that BSE infection
results in complete recapitulation of the vCJD phenotype
[28] (Figure 3). Further, it is known that human PrP
C
functions less efﬁciently in mice than mouse PrP
C,a so v e r -
expression is required to rescue a PrP null phenotype
[168] and so ‘endogenous’ levels of heterologous
PrP
C expression may not in fact be the best model of
susceptibility.
Transgenic modelling of sporadic and acquired
human prion disease
Humanized transgenic mice expressing human PrP
129 valine on a Prnp null background are highly
susceptible to sporadic CJD prions regardless of the
PrP
Sc type or codon 129 genotype of the inoculum
[25,26,58,59,122,164,169]. These transmissions are
typically characterized by 100% attack rates of prion
infection producing uniform clinical prion disease after
similar short incubation periods of around 200 days
[25,26,58,59,122,164,169]. In isolates that have been
examined, no fall in mean incubation period is seen after
secondary passage in the same mice indicative of the lack
of a transmission barrier [58].The absence of a transmis-
sion barrier to sporadic CJD prions is not, however, uni-
formlyobservedintransgenicmiceexpressinghumanPrP
129 methionine on a Prnp null background. Here mis-
match at residue 129 between the inoculum and host can
signiﬁcantlyaffecttransmission.Thuswhilethereappears
to be no barrier to transmission of sporadic CJD prions
from codon 129 methionine homozygous patients
[28,41,164,170], transmission of sporadic CJD prions
from codon 129 heterozygous patients and 129 valine
homozygous patients is often associated with more pro-
longed and variable incubation periods and reduced
attack rates [28,164,169]. Consistent with both aetiology
and the occurrence of the same PrP
Sc types that are seen
inthebrainof sporadicCJDpatients,iatrogenicCJDprions
[25,26,164,169,171] and kuru prions [122] have trans-
mission properties equivalent to those of sporadic CJD
prions. Although the precise number of distinct prion
strains that are propagated in sporadic CJD remains
unknown, Manson and colleagues have recently pre-
sented evidence for four distinct prion strains from a
limited number of sporadic CJD patients using human
PrP knock-in mice [167].
In contrast, to prions propagated in classical CJD and
kuru the transmission properties of vCJD prions are strik-
ingly distinct and have established vCJD as a distinct
human prion strain (Figures 1 and 2). Our research was
the ﬁrst to demonstrate transmission of BSE prions to
transgenic mice expressing human PrP and these data
conﬁrmed that vCJD was caused by human exposure to
the BSE prion strain [26,28] (Figure 3). The vCJD prions
transmitdiseasetowild-typemicefarmoreefﬁcientlythan
any other form of human prion disease [26,27,49,122]
and in transgenic mice faithful propagation of the vCJD
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of human PrP 129 methionine [28,49,63,170,171]
(Figure 2). Transgenic mice homozygous for human PrP
129 valine show a pronounced transmission barrier to
vCJD prions [26,49,63,166] and propagate a distinct
prion strain that has not yet been observed in humans
[26,49,171] (Figure 2). Because human PrP with 129
valine appears to be incompatible with the PrP
Sc confor-
mation propagated in vCJD [49] (Figure 2), and may have
a dominant negative inﬂuence on the propagation of
the vCJD prion strain in codon 129 heterozygous mice
[171,172],thiscouldexplainwhyallneuropathologically
conﬁrmedcasesof vCJDhavebeeninindividualshomozy-
gousfor129methionine.Whilecautionmustbeexercised
in extrapolating from animal models, even where faithful
recapitulation of molecular and pathological phenotypes
is possible [28,49,122,171], our ﬁndings, together with
more recent studies from other laboratories [63,170],
argue that primary human BSE prion infection, and
secondary infection through iatrogenic routes, will not
be restricted to a single disease phenotype. Dependent
upon the genotype of the prion source and the recipient,
the propagation of prion strains seen in sporadic CJD
or other novel prion strain types are anticipated
[28,33,49,122,171] (Figures 2 and 3). These data reiter-
atetheneedtocontinuetostratifyallhumanpriondisease
patients at the molecular level to facilitate rapid recogni-
tion of novel subtypes and change in the relative frequen-
cies of particular subtypes due to either BSE exposure
patterns or iatrogenic sources of human prions.
Conformational selection dictates human prion
strain propagation
Homozygosity at polymorphic residue 129 of human
PrP
C remains the key genetic susceptibility factor for
sporadic and acquired prion disease [50,80–84] and in
vCJD it represents the strongest known common genetic
susceptibility polymorphism in any human disease
[39,50,173]. The transgenic studies described above
have established the molecular basis for this effect by
showing that this polymorphism constrains both the
propagation of distinct human PrP
Sc conformers and
the occurrence of associated patterns of neuropathology
[25,26,28,49,122,171]. Biophysical measurements
suggest that this powerful effect of residue 129 on prion
strain selection is likely to be mediated via its effect on the
conformation of PrP
Sc or its precursors or on the kinetics
of their formation, as it has no measurable effect on the
folding, dynamics or stability of PrP
C [5,174]. Heterozy-
gosity at codon 129 is thought to confer resistance to
prion disease by inhibiting homologous protein-protein
interactions essential for efﬁcient prion replication
[80,81,171,172] while the presence of methionine or
valine at residue 129 controls the propagation of distinct
human prion strains via conformational selection
[2,5,14,49]. To date, the repertoire of PrP
Sc isoforms
that can be stably propagated by human PrP with 129
methionine or 129 valine remains unknown.
Transgenic modelling of inherited
prion disease
How pathogenic mutations in PRNP cause prion disease
has yet to be resolved; however, in most cases the muta-
tion is thought to lead to an increased tendency of PrP
C
to form PrP
Sc. However, there is now considerable evi-
dence that different mutations may have different struc-
tural consequences in the expressed protein, including
acting to destabilize the native PrP
C fold, to increase
aggregation propensity, to alter cellular trafﬁcking, or
to stabilize alternative protein (PrP
Sc) structures [175–
180]. While a wealth of data from acquired or sporadic
CJD indicates that residue 129 polymorphism criti-
Figure 3. Bovine spongiform encephalopathy (BSE) prions propagate as either variant Creutzfeldt-Jakob disease (vCJD)-like or sporadic CJD
(sCJD)-like strains in transgenic mice expressing human prion protein. Primary transmission of BSE prions in transgenic Tg(HuPrP129M
+/+
Prnp°
/°)-35 mice (Tg35) results in the propagation of either type 4 PrP
Sc and the occurrence of abundant ﬂorid PrP plaques that are the
neuropathological hallmark of vCJD or type 2 PrPSc and the occurrence of diffuse PrP deposition that is typically seen in sporadic CJD [28].
Molecular and neuropathological characteristics of these distinct prion strains remain stable after secondary passage in the same line of
transgenic mice [49]. (a,b) Representative immuno-blots of proteinase-K treated brain homogenates from vCJD and sCJD (PRNP 129 MM
genotype with type 2 PrP
Sc; sCJD T2MM) and transgenic mice analysed with antiPrP monoclonal antibody 3F4. The identity of the brain
sample is designated above each lane with the type of PrP
Sc present in the sample designated below, using the London classiﬁcation [90].
(c) Representative immunohistochemical analysis of transgenic mouse brain (thalamus) at secondary passage showing abnormal PrP
immunoreactivity, including PrP-positive plaques, stained with antiPrP monoclonal antibody ICSM 35. Scale bars: 100 mm.
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Sc
[2,5,49,52,90], the full spectrum of effects that different
pathogenic PRNP mutations have remains unclear.
However, molecular strain typing has provided important
insights into the phenotypic heterogeneity seen in inher-
ited human prion diseases. In agreement with existing
evidence that human prion strain diversity may be
generated through variance in PrP
Sc conformation and
glycosylation, cases of inherited prion disease caused
by point mutations have glycoform ratios of PrP
Sc frag-
ments distinct from those seen in both classical CJD
[103,177,181–183] and vCJD [177]. Individuals with
the same PRNP mutation can also propagate PrP
Sc with
distinct fragment sizes [103,177,184]. However, the
detection of PrP
Sc in the molecular mass range of c.
21–30 kDa is by no means a consistent feature and
some PRNP mutations, in particular those in which
amyloid plaques are a prominent feature, show
smaller protease resistant fragments of ca. 7–15 kDa
[72,103,177,181,184,185] while other PRNP muta-
tions show a consistent absence of detectable PrP
Sc
[2,72]. Collectively, these data indicate that pathogenic
PRNP mutations have diverse and direct effects on dictat-
ing the preferred structure or assembly state of mutant
PrP
Sc isoforms resulting in physicochemical properties
that are very different from the PrP
Sc types propagated in
sporadic and acquired forms of human prion disease
[74,177,186]. Notably, variable propagation of PrP
Sc
generated from wild-type PrP
C may also contribute to
phenotypic variability in inherited prion disease
[74,187–189]. Co-propagation of distinct PrP
Sc types
combined with differences in their neuropathological
targeting, abundance and potential neurotoxicity, pro-
vides a general molecular mechanism for generating
phenotypic heterogeneity in patients with the same
PRNP mutation.
Attemptstotransmitinheritedpriondiseasestononhu-
man primates [57] and wild-type mice [190–192] have
been inconclusive in answering whether all inherited
prion diseases are experimentally transmissible as nonhu-
man hosts may not be susceptible. While some inherited
prion diseases may indeed not be transmissible, and may
represent prion proteinopathies [193–195], many patho-
genic mutations have yet to be tested in transgenic mice
expressing the homotypic human mutant protein. This
may be critical as only the human mutant protein may be
conformationally susceptible to the mutant prion strain
involved [5,186]. Much of the transgenic modelling of
inherited prion disease has however focused on superim-
posing human PrP mutations onto rodent PrP
C in order
to establish whether infectious prions can be generated
de novo. To date, spontaneous neurological dysfunction
has been reported in multiple transgenic models express-
ing mutated rodent PrP. These include mice expressing
mouse PrP P101L [196], mouse PrP with octapeptide
repeat insertions [194,197–199], truncated mouse PrP
[131,200], mouse PrP with D177N and M128V substitu-
tions [201], mouse PrP with L108M, V111M and D177N
substitutions [202] and transgenic mice expressing a
counterpart of the human A117V mutation or experi-
mental mutations that favour the generation of a trans-
membrane form of PrP [193,203].
Of the various PRNP mutations studied, the proline to
leucine substitution at codon 102 (P102L) of human PrP
has been extensively investigated in different laboratories.
However, these data have been difﬁcult to interpret.
Tg(GSSPrP)174 mice expressing high levels of mouse PrP
101L spontaneously develop neurological dysfunction at
166 days of age [196], however, PrP
Sc levels are low or
undetectable, and brain extracts from affected mice do not
transmit CNS degeneration to wild-type mice, but trans-
missiontohamstersandTg(GSSPrP)196mice,expressing
lower levels of the same mutant transgene product, was
reported [204,205]. However, theseTg(GSSPrP)196 mice
have subsequently been reported to develop spontaneous
disease at advanced age [110,112] and it therefore
remains inconclusive whether transmissible prions were
generated in these transgenic mice or that the illness
observed on secondary passage simply represents accel-
eration of a spontaneous neurodegenerative disease that
is already poised to occur [65,112]. Importantly, in this
regard, transgenic mice expressing endogenous levels
of mouse PrP 101L (generated by the gene knock-in
approach) do not develop spontaneous neurodegenera-
tion [165,192] while mice over-expressing wild-type
PrP
C have been found to develop spontaneous neurologi-
cal dysfunction without generating infectious prions
[116,206–208].
Collectively, the existing data have yet to conclusively
establish whether authentic high titre infectious prions
havebeengenerateddenovoinmiceexpressingmousePrP
containing only human pathogenic mutations. In this
regard, the critical step of showing transmission to wild-
type mice on primary passage remains. An extremely
important consideration in such studies is whether super-
imposition of pathogenic human PrP mutations into
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Indeed, there are now examples of inherited prion disease
where the amino acid change thought to be pathogenic is
found as a normal variant in other mammalian species
[209–211] and critically there is now direct experimental
evidence indicating that a single analogous amino acid
change in human or mouse PrP has extremely different
structural consequences for the expressed protein. The
introduction of a tryptophan residue at amino acid posi-
tion 175 in place of the native phenylalanine has been
successfully used as an optical probe for studying the
folding dynamics of recombinant mouse PrP with no
measurable effect on the stability of the protein [212].
However, in complete contrast, introduction of the same
mutation into human recombinant PrP renders the
protein unable to fold into the native conformation [213].
Theseﬁndingsclearlyraisedoubtaboutmodellinghuman
pathogenic PrP mutations on nonhomologous PrP
sequences from other species. The possibility of propagat-
ing novel prion strains that do not recapitulate the
molecular and neuropathological phenotype of the origi-
nal human disease appears probable and for this reason it
seems clear that future transgenic models of inherited
prion disease should focus on expressing mutated human
PrP [186,214].
Of course, studies of the effects of experimental muta-
tions on mouse PrP should also continue. A recent report
of de novo generation of prion disease in such models
involvedtheintroductionof 2-pointmutationsintomouse
PrP (170N and 174T) that are found as normal variants
in the rigid loop of elk PrP [215]. Transgenic mice
mPrP(170N,174T), moderately over-expressing these
mutations spontaneously develop spongiform encephal-
opathy and PrP plaque deposition in the brain [215].
Repeated subpassages in Tg20 mice showed transmission
of disease,afteradaptation,towild-typemicebythefourth
passage,andpropagationof proteaseresistantPrP
Sc[215].
Recently,Lindquistandcolleagueshavereportedthatmice
expressing mouse PrP with L108M, V111M and D177N
substitutionsgeneratedbyknock-intechnologyspontane-
ously produce transmissible prions [202].
Difﬁculties associated with modelling human
prion disease in human PrP expressing
transgenic mice
Whether the full diversity of neuropathological pheno-
types seen in human prion disease can be faithfully
recapitulated by transgenic modelling remains an open
question. In this regard the issue of prion strain selection
or mutation will be a major factor. As recently hypoth-
esized [5] prion strains may not exist as previously
thought as molecular clones with a single PrP
Sc type
(where strain mutation in a different host would involve
generation of a distinct PrP
Sc type) but may consist of an
ensemble of molecular species (containing a dominant
PrP
Sc type that is preferentially propagated by its usual
host) from which a less populous subspecies may be
selected by an alternative host, resulting in a strain shift
or mutation. Different cellular populations and tissues
within a single host would provide different environ-
ments for strain selection as recently demonstrated in
vitro [216]. In addition, the known ability of genetic
background to inﬂuence prion strain selection
[28,50,51,117–119] means that it may be extremely dif-
ﬁcult to isolate the full complement of human prion
strains in transgenic mice having a single genetic
background.
Future perspectives
To date, the conformational repertoire of pathological
isoforms of wild-type human PrP and the various forms
of mutant human PrP has not been fully deﬁned. Bio-
chemical investigation of PrP
Sc isoforms in patients allied
with detailed clinical and neuropathological analysis will
continue to inform on the diversity of phenotypes seen in
human prion disease. As it has now become clear that
prion strain type, host genetic makeup and other factors
(e.g. route of transmission) may signiﬁcantly inﬂuence
prion disease phenotype it is expected that the actual
number of distinct human prion strains may be far less
than the number of identiﬁed phenotypes. Continued
transgenic modelling will therefore be crucial to estab-
lishing how many human prion strains exist, and what
the deﬁning molecular features of PrP
Sc are for each
strain. This information allied with comprehensive trans-
genic modelling of human BSE infection and other rel-
evant, potentially zoonotic, prion strains will inform on
how many human prion strains may have an animal
origin. Understanding the risks that existing and emerg-
ing animal prion diseases pose will have direct transla-
tion to protecting public health.
Development of an accurate classiﬁcation for human
prion disease will have major implications for epidemio-
logical research into the causes of sporadic CJD, whose
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sion of PrP
C to PrP
Sc as a rare stochastic event, or
somatic mutation of the PrP gene, resulting in expres-
sion of a pathogenic PrP mutant are plausible explana-
tions for sporadic CJD [2,74,217,218], other causes for
at least some cases, include environmental exposure to
human prions [219–221] or exposure to animal prions.
In this regard, the number of prion strains causing sheep
scrapie has yet to be established [43,45,46] and epide-
miological data cannot exclude this as a cause of a pro-
portion of cases. As future research begins to provide a
more precise understanding of the origins of human
prion disease, this will facilitate re-analysis of epidemio-
logical data, to reveal important risk factors that might
have been obscured by analysing sporadic CJD as a single
entity.
While much remains to be done in addressing funda-
mental questions about human prion strains, transmis-
sion barriers, subclinical carrier states and the role of PrP
polymorphisms and mutations in the aetiology of these
diseases and the production of prion strains, a key devel-
opment in the future will be application of these highly
characterized models to evaluate candidate therapeutic
drugs and antibodies [158,159,222]. In addition, it is
now becoming increasingly clear that genetic loci other
than PRNP may play a signiﬁcant role in prion pathogen-
esis and strain selection [117,118,223,224]. Long-term
genomic studies in both mouse and human have recently
identiﬁed a number of genes affecting prion disease incu-
bation period or susceptibility [50,51]. The characteriza-
tionof suchgenesinnewtransgenicmodelsisexpectedto
cast signiﬁcant light on pathogenic mechanisms, includ-
ing prion co-factors, and may identify new therapeutic
strategies.
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